Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Karen M. Anderson Sells 10,624 Shares

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider Karen M. Anderson sold 10,624 shares of the stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $17.32, for a total transaction of $184,007.68. Following the transaction, the insider now directly owns 71,525 shares of the company’s stock, valued at $1,238,813. This trade represents a 12.93 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Centessa Pharmaceuticals Stock Performance

Shares of CNTA traded up $0.85 during trading hours on Tuesday, hitting $17.60. The stock had a trading volume of 816,790 shares, compared to its average volume of 431,601. The firm has a 50-day moving average price of $16.53 and a 200 day moving average price of $13.40. The firm has a market capitalization of $2.32 billion, a price-to-earnings ratio of -11.50 and a beta of 1.52. Centessa Pharmaceuticals plc has a fifty-two week low of $6.65 and a fifty-two week high of $18.97. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.05. As a group, research analysts anticipate that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.

Institutional Trading of Centessa Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the company. HighMark Wealth Management LLC purchased a new position in Centessa Pharmaceuticals in the 2nd quarter valued at $840,000. TD Asset Management Inc raised its holdings in Centessa Pharmaceuticals by 40.5% in the 2nd quarter. TD Asset Management Inc now owns 321,168 shares of the company’s stock valued at $2,900,000 after acquiring an additional 92,524 shares during the last quarter. American Century Companies Inc. boosted its holdings in shares of Centessa Pharmaceuticals by 1.3% during the 2nd quarter. American Century Companies Inc. now owns 935,151 shares of the company’s stock worth $8,444,000 after purchasing an additional 12,031 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of Centessa Pharmaceuticals in the second quarter valued at approximately $148,000. Finally, Farallon Capital Management LLC increased its holdings in shares of Centessa Pharmaceuticals by 438.0% in the second quarter. Farallon Capital Management LLC now owns 1,996,000 shares of the company’s stock valued at $18,024,000 after purchasing an additional 1,625,000 shares during the last quarter. 82.01% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Guggenheim lifted their price objective on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. B. Riley began coverage on Centessa Pharmaceuticals in a report on Thursday, September 19th. They issued a “buy” rating and a $33.00 price objective for the company. BMO Capital Markets raised their price objective on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a research report on Monday, September 16th. Morgan Stanley raised Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $11.00 to $26.00 in a research report on Thursday, September 19th. Finally, Jefferies Financial Group upped their target price on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, September 11th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $25.83.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.